Bookmark and Share
BioAssay: AID 504875

Late-stage assay provider results from the probe development effort to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): luminescence-based cell-based dose response assay to determine cytotoxicity of agonist compounds Set 2

Name: Late-stage assay provider results from the probe development effort to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): luminescence-based cell-based dose response assay to determine cytotoxicity of agonist compounds Set 2. ..more
_
   
 Tested Compounds
 Tested Compounds
All(1)
 
 
Inactive(1)
 
 
 Tested Substances
 Tested Substances
All(2)
 
 
Inactive(2)
 
 
 Related BioAssays
 Related BioAssays
AID: 504875
Data Source: The Scripps Research Institute Molecular Screening Center (U-2OSCYTOX_INH_LUMI_384_CC50_SET 2)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
BioAssay Version:
Deposit Date: 2011-06-29
Hold-until Date: 2012-03-01
Modify Date: 2012-03-01

Data Table ( Complete ):           View All Data
Tested Compound:
Related Experiments
Show more
AIDNameTypeProbeComment
1509Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)Screening depositor-specified cross reference: Primary screen (S1P4 agonists in singlicate)
1523Confirmation cell-based high throughput assay for agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)Screening depositor-specified cross reference: Confirmation screen (S1P4 agonists in triplicate)
1563Counterscreen assay for S1P4 agonists: Cell-based high throughput screening assay to identify agonists of the Sphingosine 1-Phosphate Receptor 1 (S1P1)Screening depositor-specified cross reference: Counterscreen (S1P1 agonists in triplicate)
1686Fluorescence dose response cell-based high throughput screening assay for agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)Confirmatory depositor-specified cross reference: Dose response (S1P4 agonists in triplicate)
1701Fluorescence-based counterscreen assay for S1P4 agonists: Cell-based dose response high throughput screening assay to identify agonists of the Sphingosine 1-Phosphate Receptor 1 (S1P1)Confirmatory depositor-specified cross reference: Dose response counterscreen (S1P1 agonists in triplicate)
1801Summary of probe development efforts to identify agonists of Sphingosine 1-Phosphate Receptor 4 (S1P4)Summary2 depositor-specified cross reference: Summary (S1P4 agonists)
463107Late-stage fluorescence dose-response cell-based assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): Synthesized compoundsConfirmatory depositor-specified cross reference: Late stage dose response (S1P4 agonists in triplicate)
463118Late-stage fluorescence-based dose-response cell-based assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): Sphingosine 1-Phosphate Receptor 1 (S1P1) counterscreen assayConfirmatory depositor-specified cross reference: Late stage dose response counterscreen (S1P1 agonists in triplicate)
463119Late-stage assay provider results from the probe development effort to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): luminescence-based cell-based dose response assay to determine cytotoxicity of agonist compoundsConfirmatory depositor-specified cross reference: Late stage dose response counterscreen (Cytotoxicity in quadruplicate)
463122Late-stage fluorescence-based dose-response cell-based assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): Sphingosine 1-Phosphate Receptor 2 (S1P2) counterscreen assayConfirmatory depositor-specified cross reference: Late stage dose response counterscreen (S1P2 agonists in triplicate)
463123Late-stage fluorescence-based dose-response cell-based assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): Sphingosine 1-Phosphate Receptor 3 (S1P3) counterscreen assayConfirmatory depositor-specified cross reference: Late stage dose response counterscreen (S1P3 agonists in triplicate)
463129Late-stage fluorescence-based dose-response cell-based assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): Sphingosine 1-Phosphate Receptor 5 (S1P5) counterscreen assayConfirmatory depositor-specified cross reference: Late stage dose response counterscreen (S1P5 agonists in triplicate)
463225Late-stage fluorescence dose response cell-based counterscreening assay for agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): inhibition by S1P4-selective antagonistConfirmatory depositor-specified cross reference: Late stage dose response counterscreen (inhibition by S1P4-selective antagonist)
504400Late-stage counterscreen panel assay for S1P4 agonists: Ricerca HitProfilingScreen + CYP450Other depositor-specified cross reference: Late-stage counterscreen panel assay (Ricerca hit profiling CYP450)
504460Late-stage fluorescence dose response cell-based assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): purchased compounds EC50Confirmatory depositor-specified cross reference: Late-stage dose response (S1P4 agonists in triplicate)
540332Late-stage counterscreen panel assay for S1P4 agonists: Ricerca HitProfilingScreen + CYP450: Set 2Other depositor-specified cross reference
504867Late-stage fluorescence-based dose-response cell-based counterscreen assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): Sphingosine 1-Phosphate Receptor 5 (S1P5) agonist assay Set 2Confirmatory same project related to Summary assay
504869Late-stage fluorescence-based dose-response cell-based counterscreen assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): Sphingosine 1-Phosphate Receptor 5 (S1P5) antagonist assay Set 2Confirmatory same project related to Summary assay
504870Late-stage fluorescence-based dose-response cell-based counterscreen assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): Sphingosine 1-Phosphate Receptor 1 (S1P1) agonist assay Set 2Confirmatory same project related to Summary assay
504871Late-stage fluorescence-based dose-response cell-based counterscreen assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): inhibition by S1P4-selective antagonist controlConfirmatory same project related to Summary assay
504872Late-stage fluorescence-based dose-response cell-based counterscreen assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): Sphingosine 1-Phosphate Receptor 3 (S1P3) antagonist assay Set 2Confirmatory same project related to Summary assay
504873Late-stage fluorescence-based dose-response cell-based counterscreen assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): Sphingosine 1-Phosphate Receptor 2 (S1P2) agonist assay Set 2Confirmatory same project related to Summary assay
504876Late-stage fluorescence dose-response cell-based counterscreen assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): Sphingosine 1-Phosphate Receptor 4 (S1P4) antagonist assay Set 2Confirmatory same project related to Summary assay
504877Late-stage fluorescence dose-response cell-based assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): Synthesized compounds set 2Other same project related to Summary assay
504879Late-stage fluorescence-based dose-response cell-based counterscreen assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): Sphingosine 1-Phosphate Receptor 3 (S1P3) agonist assay Set 2Confirmatory same project related to Summary assay
504880Late-stage fluorescence-based dose-response cell-based counterscreen assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): Sphingosine 1-Phosphate Receptor 1 (S1P1) antagonist assayConfirmatory same project related to Summary assay
504881Late-stage fluorescence-based dose-response cell-based counterscreen assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): Sphingosine 1-Phosphate Receptor 2 (S1P2) antagonist assay Set 2Confirmatory same project related to Summary assay
504917Late-stage fluorescence-based dose-response cell-based counterscreen assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): inhibition by S1P4-selective antagonist 1.2 nMConfirmatory same project related to Summary assay
504918Late-stage fluorescence-based dose-response cell-based counterscreen assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): inhibition by S1P4-selective antagonist 0.4 nMConfirmatory same project related to Summary assay
504919Late-stage fluorescence-based dose-response cell-based counterscreen assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): inhibition by S1P4-selective antagonist 11 nMConfirmatory same project related to Summary assay
504921Late-stage fluorescence-based dose-response cell-based counterscreen assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): inhibition by S1P4-selective antagonist 33 nMConfirmatory same project related to Summary assay
504923Late-stage fluorescence-based dose-response cell-based counterscreen assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): inhibition by S1P4-selective antagonist 100 nMConfirmatory same project related to Summary assay
504924Late-stage fluorescence-based dose-response cell-based counterscreen assay to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): inhibition by S1P4-selective antagonist 3.7 nMConfirmatory same project related to Summary assay
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Center Affiliation: The Scripps Research Institute (TSRI)
Assay Provider: Michael Oldstone, TSRI
Network: Molecular Libraries Probe Production Centers Network (MLPCN)
Grant Proposal Number: U01 AI074564
Grant Proposal PI: Michael Oldstone, TSRI
External Assay ID: U-2OSCYTOX_INH_LUMI_384_CC50_SET 2

Name: Late-stage assay provider results from the probe development effort to identify agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4): luminescence-based cell-based dose response assay to determine cytotoxicity of agonist compounds Set 2.

Description:

Pandemic influenza represents a significant public health threat, due in part to immune cell-mediated lung tissue damage induced during viral infection. Sphingosine 1-phosphate (S1P) is a bioactive phospholipid released by activated blood platelets and serves to influence endothelial integrity, lung epithelial integrity (1), and lymphocyte recirculation (2-5) through five related high affinity G-protein coupled receptors. Recently, modulation of S1P receptors locally in the lungs was shown to alter dendritic cell activation and accumulation in the mediastinal lymph nodes, resulting in blunted T cell responses and control of immunopathological features of influenza virus infection (6). Reports showing that S1P5 expression is very low in dendritic cells but that S1P4 is highly expressed (7), suggest that chemical activation of the S1P4 receptor subtype in the airways could be efficient at controlling the immunopathological response to viral infection. S1P4 is coupled to Gai and Gao G-proteins and activates ERK MAPK and PLC downstream pathways (8). Thus, the identification of compounds that act as selective S1P4 agonists will provide insight into S1P4 biology and may serve as useful tools to limit lung tissue injury resulting from influenza infection.

References:

1. Sanna, M.G., J. Liao, E. Jo, C. Alfonso, M.Y. Ahn, M.S. Peterson, B. Webb, S. Lefebvre, J. Chun, N. Gray, and H. Rosen, Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem, 2004. 279(14): p. 13839-48.
2. Forrest, M., S.Y. Sun, R. Hajdu, J. Bergstrom, D. Card, G. Doherty, J. Hale, C. Keohane, C. Meyers, J. Milligan, S. Mills, N. Nomura, H. Rosen, M. Rosenbach, G.J. Shei, Singer, II, M. Tian, S. West, V. White, J. Xie, R.L. Proia, and S. Mandala, Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther, 2004. 309(2): p. 758-68.
3. Gon, Y., M.R. Wood, W.B. Kiosses, E. Jo, M.G. Sanna, J. Chun, and H. Rosen, S1P3 receptor-induced reorganization of epithelial tight junctions compromises lung barrier integrity and is potentiated by TNF. Proc Natl Acad Sci U S A, 2005. 102(26): p. 9270-5.
4. Wei, S.H., H. Rosen, M.P. Matheu, M.G. Sanna, S.K. Wang, E. Jo, C.H. Wong, I. Parker, and M.D. Cahalan, Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat Immunol, 2005. 6(12): p. 1228-35.
5. Alfonso, C., M.G. McHeyzer-Williams, and H. Rosen, CD69 down-modulation and inhibition of thymic egress by short- and long-term selective chemical agonism of sphingosine 1-phosphate receptors. Eur J Immunol, 2006. 36(1): p. 149-59.
6. Jo, E., M.G. Sanna, P.J. Gonzalez-Cabrera, S. Thangada, G. Tigyi, D.A. Osborne, T. Hla, A.L. Parrill, and H. Rosen, S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol, 2005. 12(6): p. 703-15.
7. Maeda, Y., Matsuyuki, H., Shimano, K., Kataoka, H., Sugahara, K., and Chiba, K., Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3. J Immunol, 2007. 178(6): p. 3437-46.
8. Toman, R.E. and S. Spiegel, Lysophospholipid receptors in the nervous system. Neurochem Res, 2002. 27(7-8): p. 619-27.

Keywords:

Sphingosine Receptor, Sphingosine-1-phosphate receptor 4, S1P4, EDG6, LPC1, agonist, activator, luminescence, U-2OS, cytotoxicity, CellTitre-Glo, CC50, late stage, late stage AID, powders, Scripps, Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Library Screening Center Network, MLSCN
Protocol
Assay Overview:

The purpose of this assay is to determine cytotoxicity of powder compounds identified as S1P4 agonists. In this assay, U-2OS cells are incubated with test compound, followed by determination of cell viability. The assay utilizes the CellTiter-Glo luminescent reagent to measure intracellular ATP in viable cells. Luciferase present in the reagent catalyzes the oxidation of beetle luciferin to oxyluciferin and light in the presence of cellular ATP. Well luminescence is directly proportional to ATP levels and cell viability. As designed, compounds that reduce cell viability will reduce ATP levels, luciferin oxidation and light production, resulting in decreased well luminescence. Compounds were tested in quadruplicate in a 7-point 1:3 dilution series starting at a nominal test concentration of 20 uM.

Protocol Summary:

This assay was started by dispensing U-2OS cells in McCoy's 5A medium plus 10% FBS, penicillin 100 U/mL and streptomycin 100 ug/mL (20 uL, 4 x 10E3 cells/well) into the wells of a 384-well plate. Eight 1:3 serial dilutions of compound (100 uM in growth media) were made. 5 uL of diluted compound or media were added to wells, giving final compound concentrations of 0-20 uM. The plate was incubated at 37 C in a humidified incubator for 24 hours, then equilibrated to room temperature for 30 minutes. 25 uL CellTitre-Glo reagent was added to each well, followed by incubation of the plate in the dark for 10 minutes. Well luminescence was measured on the Envision plate reader.

The % Cell Viability for each well was then calculated as follows:

%_Cell_Viability = 1 - ( Median_RFU_High_Control - RFU_Test_Compound ) / ( Median_RFU_High_Control - Median_RFU_Low_Control ) * 100

Where:

Test_Compound is defined as wells containing cells in the presence of test compound.
High_Control is defined as wells containing cells treated with media only (no compound).
Low_Control is defined as wells containing no cells (media only).

% Cell Viability was plotted against the log of the compound concentration. The CC50 is reported as "> X uM" (where X = the highest concentration tested for which > 50% Cell Viability was observed).

PubChem Activity Outcome and Score:

Compounds with a CC50 value of less than 10 uM were considered active (cytotoxic). Compounds with a CC50 value greater than 10 uM were considered inactive (non-cytotoxic).

Any compound with a percent activity value < 50% at all test concentrations was assigned an activity score of zero. Any compound with a percent activity value >= 50% at any test concentration was assigned an activity score greater than zero.

Activity score was then ranked by the potency of the compounds with fitted curves, with the most potent compounds assigned the highest activity scores.

The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.

List of Reagents:

U-2OS cells (ATCC, part HTB-96)
McCoy's 5A Medium (Invitrogen, part 16600-082)
FBS (Invitrogen, part 26140-079)
Penicillin / Streptomycin (Invitrogen, part 15140-122)
Cell Titer-Glo (Promega, part G7572)
384-well plates (Corning 3570)
Comment
This assay was performed by the assay provider with powder samples of compounds. The results of our probe development efforts can be found at http://mlpcn.florida.scripps.edu/index.php/probes/probe-reports.html.
Categorized Comment - additional comments and annotations
From PubChem:
Assay Format: Cell-based
Assay Type: Toxicity
Assay Cell Type: U-2 OS
From ChEMBL:
Assay Format: Cell-based
Assay Type: Functional
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
1QualifierActivity Qualifier identifies if the resultant data CC50 came from a fitted curve or was determined manually to be less than or greater than its listed CC50 concentration.String
2CC50*The value for concentration at which 50% of surviving cells are observed; CC50 shown in micromolar.FloatμM
3Cell Viability at 20 uM [1] (20μM**)Value of % Cell Viability at 20 uM compoun concentration; replicate [1]Float%
4Cell Viability at 20 uM [2] (20μM**)Value of % Cell Viability at 20 uM compoun concentration; replicate [2]Float%
5Cell Viability at 20 uM [3] (20μM**)Value of % Cell Viability at 20 uM compoun concentration; replicate [3]Float%
6Cell Viability at 20 uM [4] (20μM**)Value of % Cell Viability at 20 uM compoun concentration; replicate [4]Float%
7Cell Viability at 20 uM [5] (20μM**)Value of % Cell Viability at 20 uM compoun concentration; replicate [5]Float%
8Cell Viability at 20 uM [6] (20μM**)Value of % Cell Viability at 20 uM compoun concentration; replicate [6]Float%
9Cell Viability at 6.67 uM [1] (6.67μM**)Value of % Cell Viability at 6.67 uM compoun concentration; replicate [1]Float%
10Cell Viability at 6.67 uM [2] (6.67μM**)Value of % Cell Viability at 6.67 uM compoun concentration; replicate [2]Float%
11Cell Viability at 6.67 uM [3] (6.67μM**)Value of % Cell Viability at 6.67 uM compoun concentration; replicate [3]Float%
12Cell Viability at 6.67 uM [4] (6.67μM**)Value of % Cell Viability at 6.67 uM compoun concentration; replicate [4]Float%
13Cell Viability at 6.67 uM [5] (6.67μM**)Value of % Cell Viability at 6.67 uM compoun concentration; replicate [5]Float%
14Cell Viability at 6.67 uM [6] (6.67μM**)Value of % Cell Viability at 6.67 uM compoun concentration; replicate [6]Float%
15Cell Viability at 2.22 uM [1] (2.22μM**)Value of % Cell Viability at 2.22 uM compoun concentration; replicate [1]Float%
16Cell Viability at 2.22 uM [2] (2.22μM**)Value of % Cell Viability at 2.22 uM compoun concentration; replicate [2]Float%
17Cell Viability at 2.22 uM [3] (2.22μM**)Value of % Cell Viability at 2.22 uM compoun concentration; replicate [3]Float%
18Cell Viability at 2.22 uM [4] (2.22μM**)Value of % Cell Viability at 2.22 uM compoun concentration; replicate [4]Float%
19Cell Viability at 2.22 uM [5] (2.22μM**)Value of % Cell Viability at 2.22 uM compoun concentration; replicate [5]Float%
20Cell Viability at 2.22 uM [6] (2.22μM**)Value of % Cell Viability at 2.22 uM compoun concentration; replicate [6]Float%
21Cell Viability at 0.74 uM [1] (0.74μM**)Value of % Cell Viability at 0.74 uM compoun concentration; replicate [1]Float%
22Cell Viability at 0.74 uM [2] (0.74μM**)Value of % Cell Viability at 0.74 uM compoun concentration; replicate [2]Float%
23Cell Viability at 0.74 uM [3] (0.74μM**)Value of % Cell Viability at 0.74 uM compoun concentration; replicate [3]Float%
24Cell Viability at 0.74 uM [4] (0.74μM**)Value of % Cell Viability at 0.74 uM compoun concentration; replicate [4]Float%
25Cell Viability at 0.74 uM [5] (0.74μM**)Value of % Cell Viability at 0.74 uM compoun concentration; replicate [5]Float%
26Cell Viability at 0.74 uM [6] (0.74μM**)Value of % Cell Viability at 0.74 uM compoun concentration; replicate [6]Float%
27Cell Viability at 0.25 uM [1] (0.25μM**)Value of % Cell Viability at 0.25 uM compoun concentration; replicate [1]Float%
28Cell Viability at 0.25 uM [2] (0.25μM**)Value of % Cell Viability at 0.25 uM compoun concentration; replicate [2]Float%
29Cell Viability at 0.25 uM [3] (0.25μM**)Value of % Cell Viability at 0.25 uM compoun concentration; replicate [3]Float%
30Cell Viability at 0.25 uM [4] (0.25μM**)Value of % Cell Viability at 0.25 uM compoun concentration; replicate [4]Float%
31Cell Viability at 0.25 uM [5] (0.25μM**)Value of % Cell Viability at 0.25 uM compoun concentration; replicate [5]Float%
32Cell Viability at 0.25 uM [6] (0.25μM**)Value of % Cell Viability at 0.25 uM compoun concentration; replicate [6]Float%
33Cell Viability at 0.082 uM [1] (0.082μM**)Value of % Cell Viability at 0.082 uM compoun concentration; replicate [1]Float%
34Cell Viability at 0.082 uM [2] (0.082μM**)Value of % Cell Viability at 0.082 uM compoun concentration; replicate [2]Float%
35Cell Viability at 0.082 uM [3] (0.082μM**)Value of % Cell Viability at 0.082 uM compoun concentration; replicate [3]Float%
36Cell Viability at 0.082 uM [4] (0.082μM**)Value of % Cell Viability at 0.082 uM compoun concentration; replicate [4]Float%
37Cell Viability at 0.082 uM [5] (0.082μM**)Value of % Cell Viability at 0.082 uM compoun concentration; replicate [5]Float%
38Cell Viability at 0.082 uM [6] (0.082μM**)Value of % Cell Viability at 0.082 uM compoun concentration; replicate [6]Float%
39Cell Viability at 0.027 uM [1] (0.027μM**)Value of % Cell Viability at 0.027 uM compoun concentration; replicate [1]Float%
40Cell Viability at 0.027 uM [2] (0.027μM**)Value of % Cell Viability at 0.027 uM compoun concentration; replicate [2]Float%
41Cell Viability at 0.027 uM [3] (0.027μM**)Value of % Cell Viability at 0.027 uM compoun concentration; replicate [3]Float%
42Cell Viability at 0.027 uM [4] (0.027μM**)Value of % Cell Viability at 0.027 uM compoun concentration; replicate [4]Float%
43Cell Viability at 0.027 uM [5] (0.027μM**)Value of % Cell Viability at 0.027 uM compoun concentration; replicate [5]Float%
44Cell Viability at 0.027 uM [6] (0.027μM**)Value of % Cell Viability at 0.027 uM compoun concentration; replicate [6]Float%
45Cell Viability at 0 uM [1] (0μM**)Value of % Cell Viability at 0 uM compoun concentration; replicate [1]Float%
46Cell Viability at 0 uM [2] (0μM**)Value of % Cell Viability at 0 uM compoun concentration; replicate [2]Float%
47Cell Viability at 0 uM [3] (0μM**)Value of % Cell Viability at 0 uM compoun concentration; replicate [3]Float%
48Cell Viability at 0 uM [4] (0μM**)Value of % Cell Viability at 0 uM compoun concentration; replicate [4]Float%
49Cell Viability at 0 uM [5] (0μM**)Value of % Cell Viability at 0 uM compoun concentration; replicate [5]Float%
50Cell Viability at 0 uM [6] (0μM**)Value of % Cell Viability at 0 uM compoun concentration; replicate [6]Float%

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: U01 AI074564

Data Table (Concise)
Data Table ( Complete ):     View All Data
PageFrom: